This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-21. Anything still debated is marked as such rather than presented as settled.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
=== Bible verses === In-N-Out prints Bible citations in small print on areas of packaging (such as "John 3:16", "Proverbs 3:5", "Proverbs 24:16", "Nahum 1:7", "Luke 6:35" and "Revelation 3:20"). They are primarily found on the bottom underside of drink cups and the wrappers that hold their burgers together. This practice began in the 1980s during Rich Snyder's presidency, a reflection of the evangelical Christian beliefs held by the Snyder family.
== SA == sa – (s) Sanskrit language (ISO 639-1 code) SA (i) Salvation Army (s) Sand (METAR Code) Saudi Arabia (ISO 3166 and FIPS 10-4 country's code digram) (i) Sexaholics Anonymous Sexual assault (i) sine anno (Latin, "without year") Single Adult, a designation in the LDS Church for unmarried individuals 18 and older Situational awareness South Africa (i/s) South Australia (postal symbol) (i) Standards Australia Sturmabteilung (German, "Storm Detachment", Nazi forerunner and rival of SS) S.A. – designation for a corporation in many European countries; see article for meanings SAA (i) Saudi Arabian Airlines, former name of Saudia Sex Addicts Anonymous South African Airways Southern Athletic Association Standards Association of Australia, a former name of Standards Australia SAAB – (a) Svenska Aeroplan AB (Swedish aircraft manufacturer; also refers to its former auto manufacturing arm) SAAFR – (a/i) Standard use Army Aircraft Flight Route ("safer") SAAMI – (a) Sporting Arms and Ammunition Manufacturers' Institute ("sammy") SAARC – (i) South Asian Association for Regional Cooperation SAB – (i) Soprano Alto Baritone Sabena – (a) Société anonyme belge d'exploitation de la navigation aérienne (French for "Belgian Company for Exploiting Aerial Navigation", 1923–2001) SABIC – (p) Saudi Basic Industries Corporation SABR – (a) Society for American Baseball Research SAC (a) Standards Activity Committee (of SISO) U.S.
== Installations == NNPC has sole responsibility for upstream and downstream developments. In 1988, the corporation was commercialised into 11 strategic business units, covering the entire spectrum of oil industry operations: exploration and production, gas development, refining, distribution, petrochemicals, engineering, and commercial investments.
== See also == Biological half-life, the time it takes for a substance to lose half of its pharmacologic, physiologic, or radiologic activity Effective half-life, the effective radioactive half-life in organisms after accounting for excretion Half-life of knowledge, the amount of time that has to elapse before half of the knowledge or facts in a particular area is superseded or shown to be untrue Half a Life (disambiguation)
Sources: en.wikipedia.org
These observations of discrete inheritance and the segregation of alleles are collectively known as Mendel's first law or the Law of Segregation. However, the probability of getting one gene over the other can change due to dominant, recessive, homozygous, or heterozygous genes. For example, Mendel found that if you cross heterozygous organisms your odds of getting the dominant trait is 3:1. Real geneticists study and calculate probabilities by using theoretical probabilities, empirical probabilities, the product rule, the sum rule, and more.
=== Tunable resistive pulse sensing === Tunable resistive pulse sensing (TRPS) is a single-particle analytical technique used to measure the size, concentration, and charge of nano and micro-sized particles by detecting a change in ionic current. The passage of an individual particle through a charged nanopore creates a transient change in resistance and subsequent decrease in the background current, known as a blockade event. Blockade characteristics are representative of particle and sample properties: blockade magnitude is proportional to particle size, the blockade rate is directly related to particle concentration, and the speed with which a particle moves through the pore is related to its zeta potential.
The use of mist-netting and photography, blood sampling (for DNA, immunological and other studies), the development of optics and the use of other new techniques for studying birds have reduced the need to collect specimens for research, yet collections continue to act as a vital shared resource for science (particularly taxonomy) and conservation. In an era of mass extinction, bird collections will evidence lost species.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.